Literature DB >> 21844137

Qualitative research in evidence-based medicine: improving decision-making and participation in randomized controlled trials of cancer treatments.

Suzanne Audrey1.   

Abstract

BACKGROUND: Since the 1990s there has been increasing emphasis on 'evidence-based medicine'. The randomized controlled trial is widely regarded as the 'gold-standard' study design for evaluating interventions. However, placing too strong an emphasis on a phase III trial, to the neglect of earlier development and piloting work, may result in weaker interventions that are more difficult to evaluate and less likely to be implemented. AIM: To illustrate the benefits and outcomes of qualitative research at the early stages of the research continuum. SETTING/PARTICIPANTS: Two cancer studies are evaluated in which the best treatment option is uncertain: ASPECTS (A Study of Patients ExperienCes of TreatmentS) and ProtecT (Prostate Testing for Cancer and Treatment).
DESIGN: To examine decision-making in relation to palliative chemotherapy for advanced cancer, ASPECTS was a qualitative study involving non-participant observation and recording of oncology consultations. During the ProtecT feasibility study, recruitment interviews were routinely audiotaped and in-depth interviews conducted with men to explore their understanding of treatment options and randomization to trial arms.
RESULTS: ASPECTS identified that insufficient information was given to patients about the survival benefits of palliative chemotherapy with implications for informed consent. ProtecT illustrated the effective use of qualitative research methods to resolve recruitment and randomization problems for a randomized controlled trial.
CONCLUSIONS: These studies illustrate the value of qualitative research, particularly during the earlier phases of the research continuum. Such research may generate hypotheses, strengthen the development and implementation of interventions and enhance their evaluation: all of which are essential to evidence-based medicine.

Entities:  

Mesh:

Year:  2011        PMID: 21844137     DOI: 10.1177/0269216311419548

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  5 in total

1.  Using qualitative methods in pilot and feasibility trials to inform recruitment and retention processes in full-scale randomised trials: a qualitative evidence synthesis.

Authors:  Adel Elfeky; Shaun Treweek; Karin Hannes; Hanne Bruhn; Cynthia Fraser; Katie Gillies
Journal:  BMJ Open       Date:  2022-04-18       Impact factor: 3.006

2.  Development of an intervention to support patients and clinicians with advanced lung cancer when considering systematic anticancer therapy: protocol for the PACT study.

Authors:  Despina Anagnostou; Stephanie Sivell; Simon Noble; Jason Lester; Anthony Byrne; Catherine Sampson; Mirella Longo; Annmarie Nelson
Journal:  BMJ Open       Date:  2017-07-12       Impact factor: 2.692

3.  Women's experiences of medical treatment for endometriosis and its impact on PRE-EMPT trial participation: a qualitative study.

Authors:  Elaine Denny; Annalise Weckesser; Georgina Jones; Stavroula Bibila; Jane Daniels; Siladitya Bhattacharya
Journal:  Pilot Feasibility Stud       Date:  2018-11-05

4.  Factors that impact on recruitment to randomised trials in health care: a qualitative evidence synthesis.

Authors:  Catherine Houghton; Maura Dowling; Pauline Meskell; Andrew Hunter; Heidi Gardner; Aislinn Conway; Shaun Treweek; Katy Sutcliffe; Jane Noyes; Declan Devane; Jane R Nicholas; Linda M Biesty
Journal:  Cochrane Database Syst Rev       Date:  2020-10-07

5.  Barriers and facilitators experienced in collaborative prospective research in orthopaedic oncology: A qualitative study.

Authors:  J S Rendon; M Swinton; N Bernthal; M Boffano; T Damron; N Evaniew; P Ferguson; M Galli Serra; W Hettwer; P McKay; B Miller; L Nystrom; W Parizzia; P Schneider; A Spiguel; R Vélez; K Weiss; J P Zumárraga; M Ghert
Journal:  Bone Joint Res       Date:  2017-05       Impact factor: 5.853

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.